EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer-Reference-Cited by-同舟云学术

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

Published:2013-03 Issue:3 Volume:24 Page:640-647
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Dubsky P.,Filipits M.,Jakesz R.,Rudas M.,Singer C.F.,Greil R.,Dietze O.,Luisser I.,Klug E.,Sedivy R.,Bachner M.,Mayr D.,Schmidt M.,Gehrmann M.C.,Petry C.,Weber K.E.,Kronenwett R.,Brase J.C.,Gnant M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/3/640/13788599/mds334.pdf

Reference24 articles.

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Lancet,2005

2. Effect of screening and adjuvant therapy on mortality from breast cancer;Berry;N Engl J Med,2005

3. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials;Fisher;Lancet,2004

4. NCCN task force report: adjuvant therapy for breast cancer;Carlson;J Natl Compr Cancer Netw,2006

5. Strategies for subtypes––dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011;Goldhirsch;Ann Oncol,2011

Cited by 170 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selecting postoperative adjuvant systemic therapy for early‐stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays;Journal of Surgical Oncology;2024-06-24

2. Long-term prospective outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor-positive, HER2-negative early breast cancer;Breast Cancer Research and Treatment;2024-05-09

3. Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial;ESMO Open;2024-05

4. Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registry;Archives of Gynecology and Obstetrics;2024-03-12

5. Comprehensive analysis of Linc01436 for neoadjuvant chemotherapy response and its potential enriched pathways in breast cancer;2024-02-16